Loss of skin pigment caused by imatinib therapy.
McPartlin
S
S
Department of Haematology, Gartnavel General Hospital, Glasgow, Scotland, UK. shonamcp@doctors.org.uk
Leach
M
M
D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D010859:Pigmentation Disorders / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012880:Skin Pigmentation / Q000187:drug effects*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit